NLGN3 and breast carcinoma: Our findings were further validated using qRT-PCR, western blotting and immunohistochemistry which show decreased expression of NLGN3, MAML2, ANK2, and SYNE1 in breast cancer cell lines as MCF7 and MDA-MB-231 as compared to control cell line MCF10A.